Mi SciELO
Servicios personalizadosServicios Personalizados
Revista
Articulo
Inglés (pdf)
Articulo en XML
Referencias del artículo
Traducción automática
Enviar articulo por emailIndicadores
Citado por SciELO 
Accesos
Links relacionados
Citado por Google 
Similares en
SciELO 
Similares en Google
Compartir
Permalink
Revista de la OFIL
versión On-line ISSN 1699-714Xversión impresa ISSN 1131-9429
Resumen
BRICENO-CASADO, MP; RIOS-SANCHEZ, E y GIL-SIERRA, MD. Real long-term data of dupilumab in atopic dermatitis. Rev. OFIL·ILAPHAR [online]. 2020, vol.30, n.1, pp.25-27. Epub 18-Ene-2021. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x2020000100008.
Objectives:
Dupilumab is the first biological drug indicated in atopic dermatitis (AD). The aim of this study is to assess effectiveness and safety of dupilumab in moderate-severe AD in clinical practice, and the quality of life of treated patients.
Methods:
Descriptive retrospective study was conducted. Effectiveness was measured by SCORingAtopic Dermatitis (SCORAD). Primary endpoint was SCORAD-75; secondary endpoints were SCORAD-90 and “total clearance”, at week 4, 12, 24 and 48. Safety was evaluated according to adverse events profile. Quality of life was assessed by Dermatology Life Quality Index (DLQI) at week 0 and 48.
Results:
At week 4, 2 patients presented SCORAD-75, none presented SCORAD-90 or clearance. At week 12, 2 patients showed SCORAD-75, 2 SCORAD-90 and one clearance. At weeks 24 and 48, 3 patients presented SCORAD-90 and 3 clearance. All patients presented mild-moderate adverse events. DLQI at week 48 was 0.7.
Conclusions:
Dupilumab presented adequate effectiveness and safety, improving quality of life of treated patients.
Palabras clave : Atopic dermatitis; dupilumab; effectiveness; safety; quality of life.
